Towards Next-Generation Sequencing for HIV-1 Drug Resistance Testing in a Clinical Setting.

ABSTRACT: The HIV genotypic resistance test (GRT) is a standard of care for the clinical management of HIV/AIDS patients. In recent decades, population or Sanger sequencing has been the foundation for drug resistance monitoring in clinical settings. However, the advent of high-throughput or next-generation sequencing has caused a paradigm shift towards the detection and characterization of low-abundance covert mutations that would otherwise be missed by population sequencing. This is clinically significant, as these mutations can potentially compromise the efficacy of antiretroviral therapy, causing poor virologic suppression. Therefore, it is important to develop a more sensitive method so as to reliably detect clinically actionable drug-resistant mutations (DRMs). Here, we evaluated the diagnostic

SUBMITTER: Teo CHY 

PROVIDER: S-EPMC9608942 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature